

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ocumention Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1477)**

**VOLUNTARY ANNOUNCEMENT**  
**THE SIXTH PRODUCT OF THE COMPANY ENTERED PHASE III**  
**CLINICAL TRIAL STAGE – CDE APPROVAL RECEIVED FOR**  
**COMMENCEMENT OF A PHASE III CLINICAL TRIAL OF**  
**OT-502 (DEXYCU®) IN CHINA**

This announcement is made by Ocumention Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that OT-502 (DEXYCU®), one of the Group’s key drug candidates, was approved by the Center for Drug Evaluation (“**CDE**”) of the National Medical Products Administration of the People’s Republic of China to conduct a phase III clinical trial in China.

OT-502 (DEXYCU®), approved to launch in the United States by the United States Food and Drug Administration (“**FDA**”) on February 9, 2018, is the first and only FDA-approved, sustained-release intraocular drug for the treatment of postoperative inflammation indication. Inflammation is a common symptom following cataract surgery and may cause severe complications if not treated timely. To date, hormonal and antibiotic eye drops are common in clinical use to treat postoperative inflammation over two to four weeks. However, cataract surgery patients are often elderly, and their medication compliance is worse. Utilizing the drug delivery platform Verisome®, OT-502 can deliver dexamethasone into anterior chamber, directly inhibiting the synthesis and release of inflammatory mediators in anterior chamber. It works well in inhibiting responses to postoperative anterior chamber inflammation and avoids frequent use of topical hormonal eye drops, which effectively resolves non-compliance of cataract surgery patients, so as to provide a better treatment choice for the management of postoperative inflammation.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that it will ultimately commercialize OT-502 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Ocumention Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, September 14, 2021

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE and Mr. Yiran HUANG as independent non-executive directors.*